Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
Cho
Leslie
L
Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA.
Kottke-Marchant
Kandice
K
Lincoff
A Michael
AM
Roffi
Marco
M
Reginelli
Joel P
JP
Kaldus
Theresa
T
Moliterno
David J
DJ
D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy; D000925:Anticoagulants / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D010450:Endopeptidases; D005260:Female; D005343:Fibrinolytic Agents; D006629:Hirudins / Q000031:analogs & derivatives* / Q000097:blood* / Q000494:pharmacology; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D019095:Point-of-Care Systems; D011516:Prothrombin / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D014914:Whole Blood Coagulation Time
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D011516:Prothrombin; C025337:Factor IIa; D010450:Endopeptidases; C020097:ecarin; C074619:bivalirudin